PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1662649.38%
10Y CAGR of 1662649.38% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
73.02%
OCF/share CAGR of 73.02% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
60.68%
OCF/share CAGR of 60.68% while CRN.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
41.49%
3Y OCF/share CAGR of 41.49% while CRN.AX is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
84.27%
10Y net income/share CAGR of 84.27% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
93.93%
Net income/share CAGR of 93.93% while CRN.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
82.81%
3Y net income/share CAGR of 82.81% while CRN.AX is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
No Data
No Data available this quarter, please select a different quarter.
-72.32%
Negative 5Y equity/share growth while CRN.AX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
180.87%
Equity/share CAGR of 180.87% while CRN.AX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.